The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

A team of Ohio State researchers engineered a new antibody that could revolutionize influenza prevention through a nasal spray.

Parents and pediatricians will have a new option this fall to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year of age in the United ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season ...

Targeting pituitary adenylate cyclase–activating polypeptide (PACAP) is a new avenue for treating migraine. The efficacy and safety of intravenous Lu AG09222, a humanized monoclonal antibody ...

Pemivibart, a monoclonal antibody for preexposure prophylaxis for SARS-CoV-2, was recently authorized for emergency use by the FDA. The immunobridging data on which this EUA is based are presented.

“Consistent with what we previously demonstrated in animal models, these clinical data prove that our second-generation constructs increased antibody titers in humans, providing additional ...

Debates over AI antibody design terminology have clouded the industry’s shared mission of bringing better therapeutics to the clinic faster.

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using GLP-1 drugs such as Ozempic and Wegovy after losing weight.